1. Multidisciplinary Perspectives on Interstitial Lung Diseases

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

3. What Is CTD-ILD?

4. Current Understanding of the Pathophysiology of SSc-ILD

5. Diagnosing SSc-ILD

6. Evaluation of ILD in a Patient With SSc

7. Detecting ILD Diagnostic Tests

8. Thoracic HRCT of SSc-ILD

9. Is There a Role for Lung Biopsy or BAL?

10. Best Practices Within the Multidisciplinary Team for Care of Patients With SSc-ILD

11. Longitudinal Assessment of Patients With SSc Looking at Risk Factors for ILD

12. Longitudinal Assessment of Patients With Confirmed Diagnosis of SSc-ILD

13. Nonpharmacological Treatment Options

14. Current Pharmacological Treatment Options

15. Scleroderma Lung Study I

16. Scleroderma Lung Study I Outcomes at 2 Years

17. Scleroderma Lung Study II

18. Fibrosing Alveolitis in Scleroderma Trial

19. Other Immunosuppressive Treatment Options

20. Nintedanib and Pirfenidone Currently Approved Therapies for IPF

21. SENSCIS Trial Efficacy and Safety of Nintedanib in SSc-ILD

22. New and Emerging Studies for Pirfenidone

23. Concluding Remarks

24. Abbreviations

25. Abbreviations (cont)